

 INGA VENTURES PRIVATE LTD. 1229, Hubtown Solaris, N.S. Phadke Marg, Opp. Telli Galli, Andheri (East), Mumbai 400 069, Maharashtra, India CIN : U67100MH2018PTC318359 Tel. No.: +91 22 26816003; Email: foods&inns.oo@ingaventures.com; Contact Person: Kavita Shah; SEBI Registration Number: INM000012698	 Pioneer Investcorp Limited 1218, 12th Floor, Maker Chambers V, Nariman Point, Mumbai 400 021 CIN: L65990MH1984PLC031909 Tel: +91 22 66186633, E-mail: projectfood@pinc.co.in Contact Person: Varun Jain SEBI registration no.: INM000002988
--	--

August 16, 2024

To,
Foods and Inns Limited
Udyog Bhavan, 2nd Floor 29 Walchand Hirachand Marg,
Ballard Estate, Mumbai City,
Mumbai, Maharashtra,
India -400038

Dear Sir/Madam,

Sub: Submission of Post Offer Advertisement

Ref: Open Offer by Raymond Simkins (“Acquirer 1”) and Milan Bhupendra Dalal (“Acquirer 2”) (hereinafter Acquirer 1 and Acquirer 2 are collectively referred to as “Acquirers”), along with Borgos Multitrade LLP deemed to be Person Acting In Concert with Acquirer 2 (“PAC”) for the purpose of this Open Offer, to the public shareholders of Foods and Inns Limited (“Target Company”) for acquisition of upto 1,90,79,617 equity shares of face value of ₹ 1/- each at a price of ₹ 147/- per fully paid up equity share pursuant to regulations 3(1), 4 and other applicable provisions of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended (“SEBI (SAST) Regulations”).

This has reference to the captioned offer Open Offer and in terms of Regulation 18(12) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and subsequent amendments thereto (“**SEBI (SAST) Regulations**”), the Post Offer Advertisement dated August 14, 2024 has been published on August 15, 2024 in the following newspapers:

Sr. No.	Newspaper	Language	Edition(s)
1	Financial Express	English	All Editions
2	Jansatta	Hindi	All Editions
3	Pratahkal	Marathi	Marathi Editions

We are enclosing herewith a copy of the newspaper clipping of the Post Offer Advertisement published in Financial Express (English).

Kindly take the above information on your record and disseminate the Post Offer Advertisement on the website of Food and Inns Limited.

Thanking you,



INGA VENTURES PRIVATE LTD.
1229, Hubtown Solaris, N.S. Phadke Marg, Opp. Telli Galli,
Andheri (East), Mumbai 400 069, Maharashtra, India
CIN : U67100MH2018PTC318359
Tel. No.: +91 22 26816003; **Fax No.:** +91 22 26816020;
Email: foods&inns.oo@ingaventures.com;
Contact Person: Kavita Shah;
SEBI Registration Number: INM000012698

PINC

Pioneer Investcorp Limited
1218, 12th Floor, Maker Chambers V,
Nariman Point, Mumbai 400 021
CIN: L65990MH1984PLC031909
Tel: +91 22 66186633,
E-mail: projectfood@pinc.co.in
Contact Person: Varun Jain
SEBI registration no.: INM000002988

This signature page forms an integral part of this letter in relation to the proposed Open Offer of Foods and Inns Limited

For Inga Ventures Private Limited



Authorized Signatory

Name: Kavita Shah
Designation: Partner
Contact number:9867501267
Email:kavita@ingaventures.com
Encl.: As Above



INGA VENTURES PRIVATE LTD.
1229, Hubtown Solaris, N.S. Phadke Marg, Opp. Telli Galli,
Andheri (East), Mumbai 400 069, Maharashtra, India
CIN : U67100MH2018PTC318359
Tel. No.: +91 22 26816003; **Fax No.:** +91 22 26816020;
Email: foods&inns.oo@ingaventures.com;
Contact Person: Kavita Shah;
SEBI Registration Number: INM000012698

PINC

Pioneer Investcorp Limited
1218, 12th Floor, Maker Chambers V,
Nariman Point, Mumbai 400 021
CIN: L65990MH1984PLC031909
Tel: +91 22 66186633,
E-mail: projectfood@pinc.co.in
Contact Person: Varun Jain
SEBI registration no.: INM000002988

This signature page forms an integral part of this letter in relation to the proposed Open Offer of Foods and Inns Limited

For Pioneer Investcorp Limited



Authorized Signatory

Name: Deep Arora

Designation: Assistant Manager

Contact number: +91-8961088404

Email: deep.arora@pinc.co.in

Encl.: As Above

Table with 5 columns: Particulars, Standalone, Consolidated, and two sub-columns for each. Rows include Total income from operations, Net Profit, Total Comprehensive Income, etc.

Note: The above result is an extract of the detailed format of Un-audited Standalone and Consolidated Financial Results for the quarter ended 30 June 2024...

For KCD Industries India Limited Rajiv Darji Managing Director DIN: 02892193

Place: Mumbai Date: 12th August 2024

POST OFFER ADVERTISEMENT UNDER REGULATION 18 (12) OF SECURITIES AND EXCHANGE BOARD OF INDIA (SUBSTANTIAL ACQUISITION OF SHARES AND TAKEOVERS) REGULATIONS, 2011, AND AMENDMENTS THERETO

FOODS AND INNS LIMITED

CIN: L55200MH1967PLC013837 Registered Office: Uday Bhawan, 2nd Floor, 29, Waghbandi Hirchand Marg, Ballard Estate, Mumbai City, Mumbai, Maharashtra, India - 400038

Open Offer for acquisition of up to 1,90,79,617 fully paid-up equity shares of face value of ₹1 each representing 26.00% of the Expanded Voting Share Capital of Foods and Inns Limited ("Target Company")...

Table with 3 columns: Newspaper, Language, Edition(s). Lists Financial Express, Janasatta, Pratahkal in English, Hindi, and Marathi.

The Shareholders of the Target Company are requested to kindly note the following information with respect to the Open Offer:

Table with 2 columns: Particulars and Proposed in the Letter of Offer/Actuals. Details offer price, aggregate number of shares, size of the offer, etc.

Table with 2 columns: Particulars and Proposed in the Letter of Offer/Actuals. Details shareholding of acquirers, shares acquired, etc.

Percentages disclosed in the table above are computed basis the Expanded Voting Share Capital. Assuming full acceptance in the Open Offer. Excludes Brokerage and other charges.

The Acquirers, the PAC and its designated Partners accept full responsibility for the information contained in this Post Offer Advertisement and also for the obligations under SEBI (SAST) Regulations, 2011.

Capitalized terms used in this Post Offer Advertisement, but not defined herein, shall have the same meanings assigned to such terms in the Letter of Offer dated July 10, 2024. Issued by Managers to the Offer on behalf of the Acquirers and the PAC: INGA, Pinc

For and on behalf of the Acquirers and PAC: Milan Bhopendra Dalal ("Acquirer 2") Date: August 14, 2024 Place: Mumbai



GLENMARK PHARMACEUTICALS LIMITED

Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai - 400 026; Corporate Office: Western Express Highway, Andheri (E), Mumbai - 400099

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE, 2024

(All amounts in million of Indian Rupees, unless otherwise stated)

Large financial statement table with columns for Particulars, Standalone, Year ended, and Consolidated. Rows include Revenue from operations, Expenses, Profit, etc.

Notes: 1. The Financial Results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013... 2. The above results were reviewed by the Audit Committee at its meeting held on 13th August, 2024...

Exceptional item in the Standalone result for the quarter and year ended 31 March 2024 is Rs. 51,469.13 million (gain) and Rs. 50,703.31 million (gain) respectively... Exceptional item in the Consolidated result for the quarter and year ended 31 March 2024 is Rs. 4,467.85 million (loss) and Rs. 9,009.55 million (loss) respectively...

Annexure A List of entities included in the consolidated financial results for the quarter ended 30 June 2024: 1. Glenmark Pharmaceuticals Europe Ltd., U.K. 2. Glenmark Pharmaceuticals S.R.O. 3. Glenmark Pharmaceuticals SK, S.R.O. 4. Ichnos Sciences SA (Formerly known as Glenmark Pharmaceuticals S.A.) 5. Glenmark Holding S.A. 6. Glenmark Pharmaceuticals SP z.o.o. 7. Glenmark Pharmaceuticals Inc. & Glenmark Therapeutics Inc. 8. Glenmark Pharmaceuticals Ltd. 10. Glenmark Generics S.A. 11. Glenmark Pharmaceuticals Mexico, S.A. DE C.V. 12. Glenmark Pharmaceuticals Peru S.A.C. 13. Glenmark Pharmaceuticals Colombia SAS, Colombia 14. Glenmark Uruguay S.A. 15. Glenmark Pharmaceuticals Venezuela, C.A. 16. Glenmark Dominicana S.R.L. 17. Glenmark Pharmaceuticals Egypt S.A.E. 18. Glenmark Pharmaceuticals FZE 19. Glenmark Impex Ltd. 20. Glenmark Pharmaceuticals (Nigeria) Ltd. 21. Glenmark Pharmaceuticals (Malaysia) Sdn Bhd 22. Glenmark Pharmaceuticals (Australia) Pty Ltd. 23. Glenmark South Africa (pty) Ltd. 25. Glenmark Pharmaceuticals South Africa (pty) Ltd. 26. Glenmark Pharmaceuticals (Thailand) Co. Ltd. 27. Glenmark Pharmaceuticals B.V. 28. Glenmark Arzneimittel GmbH 29. Glenmark Pharmaceuticals Canada Inc. 30. Glenmark Pharmaceuticals Kenya Ltd. 31. Vivo Farmaceutica S.L. Spain 32. Glenmark Pharmaceuticals 33. Glenmark Pharmaceuticals (Brazil) Ltda. 34. Glenmark Pharmaceuticals (India) Pvt. Ltd. 35. Glenmark Pharmaceuticals (Ukraine) Ltd. 36. Glenmark Pharmaceuticals Ecuador S.A. 37. Glenmark Pharmaceuticals (Singapore) Pte. Ltd. 38. Ichnos Sciences Biopharmaceuticals SA. 39. Ichnos Sciences Inc. USA 40. Glenmark Life Sciences Limited (upto 6th March 2024) 41. Glenmark Healthcare Limited (with effect from 12th May 2023) 42. Glenmark Pharmaceuticals SPA (with effect from 1st March 2023) 43. Ichnos Pharma S.R.L. (with effect from 10th February 2024) 44. Glenmark Arzneimittel GmbH - Austria (with effect from 9th November 2023)